Off-target APOBEC activity promotes tumorigenesis by causing oncogenic driver mutations such as PIK3CA E542K or PIK3CA E545K (14) and can contribute to therapeutic resistance to tamoxifen in estrogen receptor-positive breast cancer cells (15). This evidence concerns the gene PIK3CA and breast cancer.